Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Gilead’s science is only half the battle—decoding its SEC paperwork is the other. Each 10-K can exceed 250 pages of antiviral sales data, oncology trial risk factors, and patent-expiry timelines that impact Biktarvy’s future cash flows. Add surprise 8-K material events on FDA outcomes and dozens of Form 4 insider trades from researchers at Kite Pharma, and the disclosure maze grows fast.
Stock Titan’s AI resolves that complexity. Our platform streams every Gilead Sciences SEC filing the moment it hits EDGAR and delivers plain-English summaries that pinpoint what matters: a spike in R&D spend called out in the latest "Gilead Sciences quarterly earnings report 10-Q filing," a newly granted patent buried in an exhibit, or fresh "Gilead Sciences insider trading Form 4 transactions" that hint at management’s sentiment. Interactive highlights explain cash-flow sensitivities, collaboration milestones, and CAR-T manufacturing risks so you understand "Gilead Sciences SEC filings explained simply" instead of parsing dense legal text.
Use cases include:
- Setting real-time alerts for "Gilead Sciences Form 4 insider transactions" before pivotal trial readouts.
- Comparing segment revenue across HIV, hepatitis C, and oncology lines straight from 10-Q tables.
- Reviewing "Gilead Sciences proxy statement executive compensation" to evaluate R&D incentive alignment.
- Scanning "Gilead Sciences 8-K material events explained" for FDA complete-response letters.
- Reading a "Gilead Sciences annual report 10-K simplified" summary that flags looming patent cliffs.
Whether you’re modelling drug royalties, monitoring "Gilead Sciences executive stock transactions Form 4," or just learning "understanding Gilead Sciences SEC documents with AI," our coverage gives you every filing—and the context—to make informed decisions in minutes, not hours.
Gilead Sciences, Inc. (GILD) filed a Form 4 on 07/01/2025 reporting that Chairman & CEO Daniel P. O’Day executed two open-market sales of the company’s common stock on 06/30/2025.
- Shares sold: 9,400 shares at a weighted-average price of $110.4038 and 600 shares at $111.1467, for a total of 10,000 shares.
- Remaining holdings: O’Day now directly owns 615,725 shares, down from 625,725, a reduction of roughly 1.6%.
- Trading plan: Transactions were carried out under a Rule 10b5-1 trading plan adopted on 02/28/2025, indicating pre-scheduled, automated execution.
- Price ranges: The first tranche was executed between $110.03 and $111.00; the second between $111.03 and $111.17. Detailed breakdowns are available upon request.
- No derivative securities or additional insider transactions were reported in this filing.
The filing signals continued, but limited, share disposition by the CEO within a structured trading program. Because the sale represents a small percentage of his total ownership and was executed under a 10b5-1 plan, the market impact is likely modest and largely informational rather than strategic.
Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.
The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
What is the core focus of Gilead Sciences?
How does Gilead Sciences generate revenue?
Which therapeutic areas does Gilead primarily target?
What role do strategic acquisitions play at Gilead Sciences?
How does Gilead Sciences ensure scientific rigor in its clinical trials?
What differentiates Gilead Sciences in the competitive biopharmaceutical landscape?
How does Gilead address the needs of underserved communities in its research?
What strategic value does clinical research provide to Gilead Sciences?
